Hepatic Disease in HIV-Infected Patients

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 9/4/18 (What's New)

Summary

  • NAFLD can take several forms, including NASH, and NAFLD-associated cirrhosis, which may range from harmless to life-threatening
  • Prevalence
      HIV/Hepatitis C Virus–Coinfected Patients
      • In persons coinfected with HIV and HCV, the prevalence of steatosis ranges from 40% to 70%, with higher rates observed among persons with significant hepatic fibrosis, HCV genotype 3, and exposure to NRTIs didanosine and stavudine[Macías 2012; Sulkowski 2005; Miller 2000; McGovern 2006; Marks 2005]
      • HIV-infected patients receiving ART may be at increased risk for the development of NAFLD, particularly in the setting of obesity
      HIV-Monoinfected Patients
      Clinical Presentation and Diagnosis of Nonalcoholic Steatohepatitis
        Treatment of Nonalcoholic Fatty Liver Disease
          Pharmacologic Treatment
            Treatment of Insulin Resistance
              Treatment of Dyslipidemia
                Treatment of Hepatocyte Apoptosis

              Action required